In the dynamic landscape of medtech, the fervor for artificial intelligence (AI) investment is palpable, and we expect the robust investment in AI technologies to continue, even though the meaningful impact will not materialize until beyond 2024. Though there are some noteworthy exceptions to this, such as in diagnostic imaging, the broader industry will have to wait longer for AI’s tangible use cases to drive a strong return-on-investment (ROI). A cautionary parallel is drawn from an over-enthusiastic investment in data analytics – leading to some significant localized wins, but a lot of generalized frustration in the CFO office. Keeping abreast of the developments in AI is clearly important, but keeping some financial powder dry for clearer opportunities to crystallize, use cases to unfold, and genuine value to be articulated might be warranted.